Wilson Sonsini Goodrich & Rosati represented ImmunityBio in the transaction. ImmunityBio, Inc., a clinical-stage immunotherapy company announced an up to $320 million royalty financing and equity...
Oberland Capital’s $320 Million Investment in ImmunityBio
Zymeworks’ Exclusive Licensing Agreement with Jazz Pharmaceuticals
Wilson Sonsini advised Zymeworks on the deal. Zymeworks BC Inc. and Jazz Pharmaceuticals Ireland Ltd. announced that they entered into an exclusive license agreement to develop...
ABL Bio’s License Agreement with SANOFI
Wilson Sonsini Goodrich & Rosati advised ABL on the deal. ABL Bio, Inc., a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced...
Sorriso Pharmaceuticals’ $31 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Sorriso Pharmaceuticals on the deal. Sorriso Pharmaceuticals, a biotechnology company advancing a pipeline of disease-modifying antibodies for the treatment of...
Erasca’s $345 Million Initial Public Offering
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...